CEO Mark Schurdak announced that The National Center for Advancing Translational Sciences (NCATS) funding for the commercialization of the BioSystics Platform has been renewed through November 30, 2022.
Funding from The National Center for Advancing Translational Sciences (NCATS)…
Comments are closed.